The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Open accessAbstract
Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board–approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3-D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted. Significance: Integration of genomic data with drug screening from personalized in vitro and in vivo cancer models guides precision cancer care and fuels next-generation research. Cancer Discov; 7(5); 462–77. ©2017 AACR. See related commentary by Picco and Garnett, p. 456. This article is highlighted in the In This Issue feature, p. 443
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“The high failure rate of preclinical compounds in clinical trials clearly demonstrates the limitations of existing preclinical models (7, 8).”
BackgroundCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Pan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
Deconstructing the third dimension – how 3D culture microenvironments alter cellular cues
Baker, B. M., & Chen, C. S. (2012) · Journal of Cell Science · doi:10.1242/jcs.079509 · Cited by 1,760
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationClinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, R., Muthuswamy, L. B., Crawford, H. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3973 · Cited by 740
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697 · cited 1×
“However, an understanding of the functionality of these alterations and the influence they have on treatment response remains limited due to a paucity of personalized preclinical models (14, 15).”
BackgroundThree-dimensional cell cultures: from molecular mechanisms to clinical applications
Mueller-Klieser, W. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.273.4.c1109 · Cited by 537
Oncotator: Cancer Variant Annotation Tool
Ramos, A. H., Lichtenstein, L., Gupta, M., Lawrence, M. S., Pugh, T. J., Saksena, G., Meyerson, M., & Getz, G. (2015) · Human Mutation · doi:10.1002/humu.22771 · Cited by 501
Comprehensive identification of mutational cancer driver genes across 12 tumor types
Tamborero, D., Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Kandoth, C., Reimand, J., Lawrence, M. S., Getz, G., Bader, G. D., Ding, L., et al. (2013) · Scientific Reports · doi:10.1038/srep02650 · Cited by 484
Phase III and submission failures: 2007–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Pickl, M., & Ries, C. H. (2009) · Oncogene · doi:10.1038/onc.2008.394 · Cited by 401
Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells
Cayrefourcq, L., Mazard, T., Joosse, S., Solassol, J., Ramos, J., Assenat, E., Schumacher, U., Costes, V., Maudelonde, T., Pantel, K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2613 · Cited by 372
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, H., Schultz, N., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., Heguy, A., Huberman, K., Bernstein, M., Assel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411446111 · Cited by 364
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Beltran, H., Eng, K., Mosquera, J. M., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1313 · Cited by 288
Self-citationLi, A., Walling, J., Kotliarov, Y., Center, A., Steed, M. E., Ahn, S. J., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0280 · Cited by 264
Frankel, A., Man, S., Elliott, P. J., Adams, J., & Kerbel, R. S. (2000) · PubMed · Cited by 232
Tumor biology and experimental therapeutics
MuellerKlieser, W. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00082-2 · Cited by 217
Modeling Pancreatic Cancer with Organoids
Baker, L. A., Tiriac, H., Clevers, H., & Tuveson, D. A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.004 · Cited by 210
Barbone, D., Yang, T., Morgan, J. R., Gaudino, G., & Broaddus, V. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709698200 · Cited by 162
Unraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 104
Self-citationLaBonte, M. J., Wilson, P. M., Fazzone, W., Russell, J., Louie, S. G., El-Khoueiry, A. B., Lenz, H., & Ladner, R. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2430 · Cited by 95
Rennert, H., Eng, K., Zhang, T., Tan, A. Y., Xiang, J., Romanel, A., Kim, R., Tam, W., Liu, Y., Bhinder, B., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.19 · Cited by 85
Self-citationHealth: Make precision medicine work for cancer care
Rubin, M. A. (2015) · Nature · doi:10.1038/520290a · Cited by 77
Self-citationSNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines
Demichelis, F., Greulich, H. E., Macoska, J. A., Beroukhim, R., Sellers, W. R., Garraway, L. A., & Rubin, M. A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn089 · Cited by 76
Self-citationChemical analysis of multicellular tumour spheroids
Jamieson, L. E., Harrison, D. J., & Campbell, C. J. (2015) · The Analyst · doi:10.1039/c5an00524h · Cited by 68
ASEQ: fast allele-specific studies from next-generation sequencing data
Romanel, A., Lago, S., Prandi, D., Sboner, A., & Demichelis, F. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0084-2 · Cited by 67
Self-citationGenome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma
Jiang, Y., Soong, T. D., Wang, L., Melnick, A. M., & Elemento, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040332 · Cited by 52
Self-citationMolecularly targeted drugs for metastatic colorectal cancer
Yang, H., CHENG, Y.-D., Chen, G., & Zhang, Z.-C. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s52485 · Cited by 51
An emerging role for cytopathology in precision oncology
Pauli, C., Puca, L., Mosquera, J. M., Robinson, B. D., Beltran, H., Rubin, M. A., & Rao, R. A. (2015) · Cancer Cytopathology · doi:10.1002/cncy.21647 · Cited by 33
Self-citationNash, C. E., Mavria, G., Baxter, E. W., Holliday, D. L., Tomlinson, D. C., Treanor, D. E., Novitskaya, V., Berditchevski, F., Hanby, A. M., & Speirs, V. (2015) · Oncotarget · doi:10.18632/oncotarget.3803 · Cited by 32
Molecularly targeted drugs for metastatic colorectal cancer
Cheng, Y.-D., Yang, H., Chen, G.-Q., & Zhang, Z. (2013) · Dove Medical Press (Taylor and Francis Group) · Cited by 30
Cited by
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Metadata
- Authors
- Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., McNary, T. J., Churakova, Y., Cheung, C., Triscott, J., Pisapia, D., Rao, R., Mosquera, J. M., Robinson, B., Faltas, B. M., Emerling, B. E., Gadi, V. K., Bernard, B., Elemento, O., Beltran, H., Demichelis, F., Kemp, C. J., Grandori, C., Cantley, L. C., & Rubin, M. A.
- Venue
- Cancer Discovery
- Published
- 2017-04-30
- Volume
- 7
- Issue
- 5
- Pages
- 462-477
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2601380465
- Cited by
- 937
- References
- 43
- FWCI
- 27.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.